101. Cluster headache: present and future therapy
- Author
-
Massimo Leone, Alessandro Giustiniani, and Alberto Proietti Cecchini
- Subjects
Topiramate ,medicine.medical_specialty ,Vagus Nerve Stimulation ,Gabapentin ,Calcitonin Gene-Related Peptide ,medicine.medical_treatment ,Cluster Headache ,Electric Stimulation Therapy ,Dermatology ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Animals ,Humans ,030212 general & internal medicine ,Neurostimulation ,rhinorrhea ,Sumatriptan ,business.industry ,Cluster headache ,General Medicine ,medicine.disease ,Surgery ,Psychiatry and Mental health ,Verapamil ,Anesthesia ,Occipital nerve stimulation ,Neurology (clinical) ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Vagus nerve stimulation ,Forecasting ,medicine.drug - Abstract
Cluster headache is characterized by severe, unilateral headache attacks of orbital, supraorbital or temporal pain lasting 15-180 min accompanied by ipsilateral lacrimation, rhinorrhea and other cranial autonomic manifestations. Cluster headache attacks need fast-acting abortive agents because the pain peaks very quickly; sumatriptan injection is the gold standard acute treatment. First-line preventative drugs include verapamil and carbolithium. Other drugs demonstrated effective in open trials include topiramate, valproic acid, gabapentin and others. Steroids are very effective; local injection in the occipital area is also effective but its prolonged use needs caution. Monoclonal antibodies against calcitonin gene-related peptide are under investigation as prophylactic agents in both episodic and chronic cluster headache. A number of neurostimulation procedures including occipital nerve stimulation, vagus nerve stimulation, sphenopalatine ganglion stimulation and the more invasive hypothalamic stimulation are employed in chronic intractable cluster headache.
- Published
- 2017
- Full Text
- View/download PDF